Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of MAKO Surgical
So what: RIO system sales came in at just nine systems, following up its disappointing first quarter, which saw only six systems sold. There were a total of 2,590 MAKOplasty procedures performed during the quarter, which was a 66% increase over last year. The company also sold nine total hip arthroplasty applications.
Now what: MAKO has had a rough year so far, even when acknowledging the back-end-loaded nature of its business with most purchases usually taking place during the latter half of each year. CEO Maurice Ferre expressed optimism in long-term growth, but said the company's near-term focus will be improving execution. For the second consecutive quarter, MAKO has now slashed full-year RIO system sales guidance and now expects to sell only 42 to 48 systems this year.
Interested in more info on MAKO Surgical? Add it to your watchlist by clicking here.
Fool contributor Evan Niu owns shares of MAKO Surgical, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of MAKO Surgical. Motley Fool newsletter services have recommended buying shares of MAKO Surgical. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Why Do You Still Own MAKO Surgical?
MAKO Surgical is trading near 52-week-highs, but that's not why one Fool thinks it's a bad idea to own the stock right now.
What Medtronic Needs to Beat the Stryker-MAKO Merger
Medtronic is a giant in the medical-device industry, and even though Stryker's acquisition of MAKO Surgical will present some challenges, it can still stay on top.
MAKO Surgical Q3 Revenues Drop, Net Loss Deepens
The bottom-line shortfall is more than three times that of Q3 2012.